IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.190
+0.010 (0.85%)
Apr 25, 2025, 4:00 PM EDT - Market closed
IceCure Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for IceCure Medical stock has a target of 2.50, which predicts an increase of 110.08% from the current stock price of 1.19.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for IceCure Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +110.08% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +110.08% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +110.08% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +110.08% | Sep 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $2.5 | Strong Buy | Maintains | $3 → $2.5 | +110.08% | Aug 21, 2024 |
Financial Forecast
Revenue This Year
6.48M
from 3.29M
Increased by 97.02%
Revenue Next Year
20.29M
from 6.48M
Increased by 212.86%
EPS This Year
-0.27
from -0.30
EPS Next Year
-0.16
from -0.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.6M | 34.3M | 63.0M | ||
| Avg | 6.5M | 20.3M | 61.2M | ||
| Low | 3.9M | 7.0M | 58.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 252.7% | 428.9% | 210.6% | ||
| Avg | 97.0% | 212.9% | 201.7% | ||
| Low | 17.6% | 7.6% | 189.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.26 | -0.07 | 0.23 | ||
| Avg | -0.27 | -0.16 | 0.22 | ||
| Low | -0.27 | -0.24 | 0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.